Dreamgenics signs scientific-technological collaboration agreement with FINBA

FINBA-Building

The Foundation for Biosanitary Research and Innovation of Asturias (FINBA) and Dreamgenics have signed a framework agreement of institutional collaboration for the scientific-technological development and biosanitary innovation in Asturias with the aim of carrying out research projects in the field of Personalized Precision Medicine. FINBA has ... Read more

Application of UMIs in genomic studies

UMIs (Unique Molecular Identifiers), also known as "molecular barcodes", were first introduced in high-throughput sequencing or Next-generation Sequencing (NGS) experiments more than a decade ago. These codes consist of different short oligonucleotide sequences that are uniquely added to each DNA molecule prior to sequencing, and ... Read more

Dreamgenics signs a collaboration agreement with Universidad Europea

Dreamgenics has as a fundamental objective of its activity as a biotechnology company to collaborate in the development of Precision Medicine, and to achieve this, it is essential to establish close links with prestigious institutions and research centers. For this reason, it has reached a collaboration agreement with the European University. With this collaboration, both institutions will ... Read more

The role of IncRNAs as potential biomarkers and therapeutic targets in cancer.

Non-coding RNAs (ncRNAs) are RNA molecules without protein translation potential, but capable of modulating gene expression through different mechanisms. The ncRNA-mediated gene silencing constitutes an important type of epigenetic alterations and has been implicated in several human carcinogenesis. A growing number of studies have uncovered ... Read More

Present and future of genomic medicine in cardiovascular diseases

Since the 1990s, genetic testing in cardiology has been recommended for patients who have symptoms of inherited cardiovascular disease or are at high risk because there is a known pathogenic variant in their family. In 2020, the American Heart Association (AHA) issued a statement recommending genetic testing for patients diagnosed with an inherited cardiovascular ... Read More

Need for new biomarkers for clinical diagnosis of rheumatoid arthritis

Rheumatoid arthritis (RA) is a multifactorial, inflammatory and progressive autoimmune disease, most commonly found in people between the ages of 45 and 55, which mainly affects the joints, although it can also affect other parts of the body. It begins with a destruction of the synovial membrane that covers the joints, causing a picture of pain, swelling and ... Read More

Differential expression studies at the gene and protein level in Precision Medicine.

The development of omics technologies in recent years has led to an increasing understanding of the pathophysiology of diseases and the discovery of potential biomarkers that can improve the diagnosis, prognosis and monitoring of how a disease responds to different treatments. This increase in the number of possible variables involved in the onset of disease is ... Read More